A renewed bid from Pfizer for AstraZenica could excite the stock market and stimulate merger and acquisition activity among utilities. Nigel Hawkins identifies the potential targets.
A utility shake-up in 2015?
A renewed bid from Pfizer for AstraZenica could excite the stock market and stimulate merger and acquisition activity among utilities. Nigel Hawkins identifies the potential targets.